ES2941771T3 - Derivados de dihidrocromeno - Google Patents
Derivados de dihidrocromeno Download PDFInfo
- Publication number
- ES2941771T3 ES2941771T3 ES19770755T ES19770755T ES2941771T3 ES 2941771 T3 ES2941771 T3 ES 2941771T3 ES 19770755 T ES19770755 T ES 19770755T ES 19770755 T ES19770755 T ES 19770755T ES 2941771 T3 ES2941771 T3 ES 2941771T3
- Authority
- ES
- Spain
- Prior art keywords
- spiro
- pyrano
- benzopyran
- dihydro
- imidazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018052971 | 2018-03-20 | ||
| PCT/JP2019/011439 WO2019181939A1 (ja) | 2018-03-20 | 2019-03-19 | ジヒドロクロメン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2941771T3 true ES2941771T3 (es) | 2023-05-25 |
Family
ID=67986459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19770755T Active ES2941771T3 (es) | 2018-03-20 | 2019-03-19 | Derivados de dihidrocromeno |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10807993B2 (https=) |
| EP (1) | EP3770162B1 (https=) |
| JP (4) | JP6733072B2 (https=) |
| KR (1) | KR102799186B1 (https=) |
| CN (1) | CN111886237B (https=) |
| AU (1) | AU2019239481B2 (https=) |
| CA (1) | CA3092255A1 (https=) |
| CY (1) | CY1126034T1 (https=) |
| DK (1) | DK3770162T3 (https=) |
| EA (1) | EA202092206A1 (https=) |
| ES (1) | ES2941771T3 (https=) |
| FI (1) | FI3770162T3 (https=) |
| HU (1) | HUE062256T2 (https=) |
| MX (1) | MX2020009763A (https=) |
| MY (1) | MY202583A (https=) |
| PH (1) | PH12020551497A1 (https=) |
| PL (1) | PL3770162T3 (https=) |
| PT (1) | PT3770162T (https=) |
| SG (1) | SG11202007979UA (https=) |
| TW (1) | TWI899051B (https=) |
| WO (1) | WO2019181939A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3770162T3 (pl) * | 2018-03-20 | 2023-06-05 | Sumitomo Pharma Co., Ltd. | Pochodne dihydrochromenu |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2025100519A1 (ja) * | 2023-11-09 | 2025-05-15 | 住友ファーマ株式会社 | ジヒドロクロメン誘導体を含むがんの治療剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001045707A1 (en) | 1999-12-21 | 2001-06-28 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US20090111805A1 (en) | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| US20080255149A1 (en) * | 2005-09-27 | 2008-10-16 | Novartis Ag | Carboxyamine Compounds and Methods of Use Thereof |
| EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| RU2018101897A (ru) * | 2015-06-22 | 2019-07-24 | Сумитомо Дайниппон Фарма Ко., Лтд. | Бициклическое гетероциклическое амидное производное |
| CA2990583A1 (en) | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-disubstituted imidazole derivative |
| JP6896701B2 (ja) * | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| TW201821105A (zh) * | 2016-10-20 | 2018-06-16 | 美商弗瑪治療公司 | 使用ｈｄａｃ１１抑制劑之方法 |
| PL3770162T3 (pl) | 2018-03-20 | 2023-06-05 | Sumitomo Pharma Co., Ltd. | Pochodne dihydrochromenu |
| JP2020019752A (ja) | 2018-08-03 | 2020-02-06 | 大日本住友製薬株式会社 | クロマン誘導体 |
-
2019
- 2019-03-19 PL PL19770755.7T patent/PL3770162T3/pl unknown
- 2019-03-19 TW TW108109362A patent/TWI899051B/zh active
- 2019-03-19 AU AU2019239481A patent/AU2019239481B2/en active Active
- 2019-03-19 PT PT197707557T patent/PT3770162T/pt unknown
- 2019-03-19 MX MX2020009763A patent/MX2020009763A/es unknown
- 2019-03-19 SG SG11202007979UA patent/SG11202007979UA/en unknown
- 2019-03-19 MY MYPI2020004784A patent/MY202583A/en unknown
- 2019-03-19 WO PCT/JP2019/011439 patent/WO2019181939A1/ja not_active Ceased
- 2019-03-19 HU HUE19770755A patent/HUE062256T2/hu unknown
- 2019-03-19 FI FIEP19770755.7T patent/FI3770162T3/fi active
- 2019-03-19 EP EP19770755.7A patent/EP3770162B1/en active Active
- 2019-03-19 CN CN201980020335.0A patent/CN111886237B/zh active Active
- 2019-03-19 EA EA202092206A patent/EA202092206A1/ru unknown
- 2019-03-19 DK DK19770755.7T patent/DK3770162T3/da active
- 2019-03-19 KR KR1020207029401A patent/KR102799186B1/ko active Active
- 2019-03-19 ES ES19770755T patent/ES2941771T3/es active Active
- 2019-03-19 CA CA3092255A patent/CA3092255A1/en active Pending
- 2019-03-19 JP JP2020507833A patent/JP6733072B2/ja active Active
-
2020
- 2020-03-03 US US16/808,246 patent/US10807993B2/en active Active
- 2020-07-08 JP JP2020117566A patent/JP7247144B2/ja active Active
- 2020-07-31 US US16/944,482 patent/US11639357B2/en active Active
- 2020-09-18 PH PH12020551497A patent/PH12020551497A1/en unknown
-
2023
- 2023-03-15 JP JP2023040667A patent/JP7508620B2/ja active Active
- 2023-03-21 US US18/187,124 patent/US12398149B2/en active Active
- 2023-05-26 CY CY20231100250T patent/CY1126034T1/el unknown
-
2024
- 2024-06-19 JP JP2024098472A patent/JP2024123117A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2773138T3 (es) | Derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1H-pirrolo[2,3-c]piridina como inhibidores de NIK para el tratamiento del cáncer | |
| US12364702B2 (en) | Highly active sting protein agonist compound | |
| US20260015363A1 (en) | Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof | |
| US12398149B2 (en) | Dihydrochromene derivatives | |
| ES2718557T3 (es) | Nuevos compuestos como inhibidores de nik | |
| ES2991898T3 (es) | Derivado de piperidina con puente ópticamente activo | |
| JP2024521791A (ja) | 脳又はｃｎｓへの癌転移を治療するためのｅｇｆｒデグレーダー | |
| US12410188B2 (en) | Adenosine receptor antagonist | |
| JP7287929B2 (ja) | ジヒドロクロメン誘導体を含有する医薬 | |
| JP2020019752A (ja) | クロマン誘導体 | |
| WO2021172359A1 (ja) | Ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム | |
| HK40043696B (en) | Dihydrochromene derivatives | |
| HK40043696A (en) | Dihydrochromene derivatives | |
| US12617779B2 (en) | Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same | |
| BR112020017481B1 (pt) | Derivados de di-hidrocromeno, seu uso e composição farmacêutica | |
| US20240368138A1 (en) | Self degradation-type cdk9 inhibitor prodrug and liposome encapsulating same |